Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [3]
- Immunohistochemistry [3]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-36614 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-ADD1/ADD2 (Ser726, Ser713) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody detects endogenous protein at a molecular weight of 81 kDa.
- Concentration
- 1 mg/mL
Submitted references Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer's disease.
Ferrer I, Andrés-Benito P, Ausín K, Pamplona R, Del Rio JA, Fernández-Irigoyen J, Santamaría E
Brain pathology (Zurich, Switzerland) 2021 Nov;31(6):e12996
Brain pathology (Zurich, Switzerland) 2021 Nov;31(6):e12996
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-ADD1 pSer726+ADD2 pSer713 using Phospho-ADD1 pSer726+ADD2 pSer713 polyclonal antibody (Product # PA5-36614) at a dilution of 1:500. Lane 1: Hela cell lysate treated with PMA, Lane 2: SP2/0 cell lysate treated with PMA, Lane 3: PC12 cell lysate treated with PMA.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-ADD1/ADD2 (Ser726, Ser713) in Lane 1: HeLa whole cell lysate (40 µg), Lane 2: HeLa treated with PMA (60 ng/mL, 30 min) whole cell lysate (40 µg), Lane 3: PC12 whole cell lysate (40 µg), Lane 4: PC12 treated with PMA (60 ng/mL, 30 min) whole cell lysate (40 µg). Samples were incubated with Phospho-ADD1/ADD2 (Ser726, Ser713) polyclonal antibody (Product # PA5-36614) at a dilution of 1:500.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-ADD1/ADD2 (Ser726, Ser713) in Lane 1: HeLa cell lysate treated with PMA, Lane 2: SP2/0 cell lysate treated with PMA, Lane 3: PC12 cell lysate treated with PMA. Samples were incubated with Phospho-ADD1/ADD2 (Ser726, Ser713) polyclonal antibody (Product # PA5-36614) at a dilution of 1:500.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Phospho-ADD1/ADD2 (Ser726, Ser713) in paraffin-embedded human rectum carcinoma tissue (membrane and cytoplasmic staining) and negative control (right, with PBS only). Samples were incubated with Phospho-ADD1/ADD2 (Ser726, Ser713) polyclonal antibody (Product # PA5-36614) at a dilution of 1:50, followed by goat Anti-Rabbit IgG-biotin and avidin peroxidase.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Phospho-ADD1/ADD2 (Ser726, Ser713) in paraffin-embedded human breast carcinoma tissue (cytoplasm and membrane staining) and negative control (right, with PBS only). Samples were incubated with Phospho-ADD1/ADD2 (Ser726, Ser713) polyclonal antibody (Product # PA5-36614) at a dilution of 1:50, followed by goat Anti-Rabbit IgG-biotin and avidin peroxidase.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Phospho-ADD1 pSer726+ADD2 pSer713 in paraffin-embedded human colorectal carcinoma using Phospho-ADD1 pSer726+ADD2 pSer713 polyclonal antibody (Product # PA5-36614) at a dilution of 1:50.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 7 Immunohistochemistry of selected phosphorylated proteins in the EC at different stages of NFT pathology (stages I-II, III-IV, and V-VI of Braak). Phosphorylated catenin-beta and p38-P immunoreactivity appear at the first and middle stages of NFT pathology as small granules in the cytoplasm of a subpopulation of neurons. This pattern is also found for p38-P in many neurons of the EC at stages V-VI of NFT pathology. MAP2-P, NFL-P, and SAPK/JNK-P immunoreactivity is found in neurons with the morphology of NFTs from the first stages onwards; the number of affected neurons increases with disease progression. The number of NFL-P-positive neurons is, by far, smaller than the number of neurons with MAP2-P pathology in consecutive sections. PAK1-P immunoreactivity is seen in NFTs at stages III-IV and V-VI, but as irregular or granular deposits in EC neurons at staged I-II. ADD1-P immunoreactivity increases in astrocytes and in a subpopulation of NFTs at middle and advanced stages of NFT pathology. Paraffin sections, lightly counterstained with hematoxylin, bar = 50 mum